 Patients with coronary heart disease CHD or CHD equivalent e. g. diabetes mellitus often have abnormalities in lipids hypercholesterolemia. Besides, hypercholesterolemia is an evident risk factor for atherosclerosis. Hitherto, there are only few studies of patients with primary hypercholesterolemia where the combination therapy with statins HMG-Co-reductase inhibitors and ezetimib was investigated. This combination therapy should be more effective in reducing low density lipoprotein cholesterol LDL-C and total cholesterol levels compared to monotherapy. 